Bearish
ADC Therapeutics falls on confirmatory trial data for lymphoma therapy
ADC Therapeutics (ADCT) shares fell following the announcement of confirmatory Phase 3 trial data for their lymphoma therapy, ZYNLONTA, at the ASCO an...